Genome-wide losses of DNA methylation have been regarded as a common epigenetic event in malignancies and may play crucial roles in carcinogenesis. Limited information is available on the global methylation status in normal tissues and other cancer types beyond colonic carcinoma. Here we applied the combined bisulfite restriction analysis PCR to evaluate the methylation status of LINE-1 repetitive sequences in genomic DNA derived from microdissected samples from several human normal and neoplastic tissues. We found that methylation of LINE-1 in leukocytes was independent of age and gender. In contrast, normal tissues from different organs showed tissue-specific levels of methylated LINE-1. Globally, most carcinomas including breast, colon, lung, head and neck, bladder, esophagus, liver, prostate, and stomach, revealed a greater percentage of hypomethylation than their normal tissue counterparts. Furthermore, DNA derived from sera of patients with carcinoma displayed more LINE-1 hypomethylation than those of noncarcinoma individuals. Finally, in a colonic carcinogenesis model, we detected significantly greater hypomethylation in carcinoma than those of dysplastic polyp and histological normal colonic epithelium. Thus, the methylation status is a unique feature of a specific tissue type and the global hypomethylation is a common epigenetic process in cancer, which may progressively evolve during multistage carcinogenesis.
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In this current study, we apply a modified COBRA PCR protocol to efficiently and quantitatively evaluate LINE-1 methylation status in the whole genome of isolated cell populations. This new protocol targets shorter amplicon sizes of the widely distributed LINE-1 sequences, which greatly improve yield when amplifying genetic material derived from microdissected paraffinembedded tissue. The outline of the new COBRA LINE-1 is illustrated in Figure 1a . Unmethylated cytosines in DNA samples were changed to uracil by treatment with sodium bisulfite. The modified DNA was amplified by 5 0 UTR LINE-1 bisulfited sequence primers and then digested with TaqI and TasI restriction enzymes, which recognize methylated and unmethylated sequences, respectively. The level of LINE-1 hypomethylation in each sample was calculated by dividing the measured intensity of TasI digestible amplicons with the sum of TasI and TaqI products (Figure 1a and b) .
We confirmed the presence of only TasI or TagI restriction site in digestible PCR products from two cell lines, Daudi and K562, by subcloning the PCR products and DNA sequencing. All TasI-or TagI-positive clones revealed complete unmethylation or methylation of all Figure 1 Combined bisulfite restriction analysis of LINE-1 (COBRA LINE-1). We used 5 0 UTR of LINE-1.2 sequence from NCBI Accession Number M80343. DNA isolation and extraction from leukocytes, sera, and unstained microdissected paraffin-embedded tissues and treatment with bisulfite have been described previously (Herman et al., 1996; Xiong and Laird, 1997; Mutirangura et al., 1998 Mutirangura et al., , 1999 . Bisulfited DNA was subjected to 35 cycles of PCR with two primers, 5 0 -CCGTAAGGGGTTAGGGAGTTTTT-3 0 and 5 0 -RTAAAACCCTCCRAACCAAATATAAA-3 0 , with an annealing temperature of 501C. The amplicons were digested in 10 ml reaction volume with 2 U of TaqI or 8 U of TasI in 1 Â TaqI buffer (MBI fermentas) at 651C overnight and were then electrophoresed in 12% nondenaturing polyacrylamide gel. Intensities of DNA fragments were measured by PhosphorImager using Image Quant software (Molecular Dynamics). LINE-1 methylation level was calculated as a percentage of intensity of TaqI divided by the sum of TaqI-and TasI Southern blotting of HpaII digested DNA was performed as described previously, with some modifications (Kaneda et al., 2004) . We used probes targeting nucleotides 48-515 of the LINE-1.2 amplicons. Methylation level was semiquantitatively calculated as a percentage of measured hybridization intensities in the 2-4 kb region divided by those in the 0.4-4 kb region. Methylation levels of DNA from K562, Hela, Molt4, Daudi, and sperm analysed by Southern blotting and COBRA LINE-1 were plotted on X-and Y-axis, respectively. (e) Intra-and inter-assay variations of COBRA LINE-1. We used several mixed sperm and K562 DNA concentrations and repeated COBRA LINE-1 experiments at different occasions to validate the inter-assay variation. Several analyses of samples were performed to determine the intra-assay variation. The bar value is the mean and error bars represent ranges across experiments Global hypomethylation in normal tissues and cancers K Chalitchagorn et al linked CpG dinucleotides, respectively ( Figure 1c ). To validate this newly improved assay, we analysed the methylation status from four malignancy cell lines and sperm DNA by COBRA LINE-1 or previously published Southern blotting with the hybridization method (Kaneda et al., 2004) . We found a linear correlation of the methylation levels analysed by the current technique with the semiquantitative conventional Southern blotting hybridization assay (Figure 1d ). Furthermore, we validated the reliability of COBRA LINE-1 assay by performing calibration experiments using highly methylated genomic DNA from sperm mixed with highly unmethylated genomic DNA from K562. The results demonstrated consistencies of the current approach with minimal intra-and inter-variations (Figure 1d ). We anticipated that gender, age (Lyon, 1994; Cui et al., 2003) , and cellular differentiation might influence the results of COBRA LINE-1 when analysing normal and cancer genome. We evaluated COBRA LINE-1 of leukocytes from the peripheral blood of 16 women and 16 men. In each group, half of the subjects were younger than 40 years. There was no difference in the level of LINE-1 methylation between males and females (P>0.1), or between the elderly and the young (P>0.2) (Figure 2a and Table 1 ). We next sought to characterize the levels of genomic methylation among normal tissues. Interestingly, in most cases, the distribution of detected LINE-1 hypomethylation within individual normal tissue was consistently clustered within 5% range, whereas the levels of hypomethylation in thyroid (42.61-73.71%) and esophageal tissue (34.42-68.49%) were widely distributed (Figure 2b and Table 1) . Strikingly, the levels of LINE-1 methylation demonstrated by COBRA were significantly different among different tissue types (Figure 2b and Table 1 ). Our data suggest that this epigenetic event may be continuously altered in adult tissues by the processes of cellular differentiation, in addition to the previously described hypomethylation process occurring during gametogenesis and embryonic development (Reik et al., 2001 ). Additionally, the individual level of global methylation in a specific tissue type should be taken into consideration when studying the LINE-1 hypomethylation in cancer development. We further evaluated the differential level of LINE-1 methylation between normal tissues and cancers in a broad panel of malignancies including urothelial Figure 2 LINE-1 hypomethylation levels in several tissue types. Circles, triangles, and squares are levels of COBRA LINE-1 from normal, malignant, and premalignant tissues, respectively. The vertical axis displays percentage levels of LINE-1 methylation. Sample types are labeled. (a-d) are the hypomethylation levels of leukocytes, cancers, microdissected colonic tissues, and sera, respectively. Single, double, and triple asterisks indicate significant differences in hypomethylation levels between normal tissues and the tested samples at Po0.05, o0.01, and o0.001, respectively. HNSC stands for head and neck squamous cell. N and T are normal and malignant tissues, respectively Global hypomethylation in normal tissues and cancers K Chalitchagorn et al carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small-cell lung carcinoma, renal cell carcinoma, prostatic adenocarcinoma, gastric adenocarcinoma, malignant lymphoma, papillary carcinoma of thyroid, mammary ductal carcinoma, and esophageal squamous cell carcinoma. For this purpose, we manually microdissected paraffin-embedded samples to isolate malignant cells from their adjacent normal epithelium or connective tissues. Lymphomas were compared to reactive lymph nodes from sex-and age-matched individuals. We detected significantly greater hypomethylation in most cancers, including carcinomas of urinary bladder, head and neck, liver, lung, prostate gland, stomach, colon, breast, and esophagus than their normal tissue counterparts ( Figure  2b , c and Table 1 ). However, the levels of LINE-1 hypomethylation in lymphoma, renal cell carcinoma, and papillary carcinoma of thyroid were not significantly different from their normal tissues. Considering the distribution of LINE-1 hypomethylation level, we found that an individual malignancy displayed a certain degree of correlation with the methylation status of its normal tissue. For example, there were wide ranges of COBRA LINE-1 hypomethylation within esophageal carcinoma (50.10-77.39%) and their normal counterparts (34.42-68.49%), whereas those of urothelial carcinomas (65.37-70.98% in cancer and 64.36-65.90% in normal tissue) were relatively clustered. The mean increased level of hypomethylation ranged from 3 to 6% in most cancers, but increased by 2.82% in prostate and 10.58% in esophageal carcinomas (Figure 3) . It is interesting to note that there were possible two groups of differential genomic hypomethylation in cancers, low (0-3.4%) or moderately high group (6.8-9.5), as demonstrated in gastric, head and neck, and colonic carcinoma (Figure 3) . Collectively, our findings are consistent with the previous notion that global hypomethylation is a common epigenetic event in cancer.
An additional panel of colonic tissues was selected as a model to address the roles of LINE-1 hypomethylation in the multistep carcinogenesis. We found a prominent LINE-1 hypomethylation in the late stage of malignant progression evidenced by significantly more hypomethylation in colonic carcinoma compared to dysplastic polyps (Po0.01) and normal epithelium (Po0.01). Under our COBRA LINE-1 protocol, though adenomatous polyps appeared to be more hypomethylated than normal epithelium, the difference did not reach statistical significance (P ¼ 0.102) (Figure 2c and Table 1 ). The higher measured LINE-1 (A), (B), (C), and (D) were comparisons of genomic hypomethylation between normal peripheral blood leukocytes of different sex or age, cancer and normal counterpart, microdissected tissue types of colon, sera of stomach cancer patients and matched sex and age control individuals, respectively. % hypomet, percentage level of LINE-1 hypomethylation; P, P-value; 95% CI, 95% confidence interval of the difference; o and >40 years, age below or above 40 years old, respectively; CNT, connective tissue; Polyp, dysplastic polyp; P-value and 95% CI were calculated by paired t-test one-tailed analysis of most cases besides a and b. P-value and 95% CI calculated by unpaired t-test one-tailed analysis; b, P-value and 95% CI calculated by paired t-test two-tailed analysis
Global hypomethylation in normal tissues and cancers K Chalitchagorn et al hypomethylation in carcinoma strongly suggests that global hypomethylation is a progressive process developing during tumor progression, in addition to previous evidence of genomic and LINE-1 hypomethylation occurring as an early event in colonic carcinogenesis (Goelz et al., 1985; Suter et al., 2004) . We further investigated whether COBRA LINE-1 might be a potential tumor marker. Since circulating DNA in plasma or serum has recently become a promising tumor marker (Anker and Stroun, 2000), we evaluated LINE-1 hypomethylation in circulating DNA derived from the serum of 17 gastric carcinoma patients, together with 17 age-and sex-matched controls. Sera from the cancer patients consistently demonstrated greater hypomethylation levels (56.24-72.59%) as compared to the matched controls (53.20-66.79%), with a statistical significance (Po0.05) (Figure 2d and Table 1) . Nevertheless, the level of LINE-1 hypomethylation in free circulating DNA increased modestly and significantly overlapped. This application of the COBRA LINE-1 as a potential tool to screen cancer is, therefore, limited.
Our new COBRA LINE-1 protocol could consistently detect 3-6% increases in the level of global methylation in cancerous compared to normal tissue. This modest difference in genomic hypomethylation may actually represent an alteration equivalent to a change of one or two whole chromosomes. This magnitude of change in the global methylation may be critical to cells, since the comparable level of change, such as the double doses of partially activated X chromosome by X-autosome translocation, observed as a type of skewed X-inactivation in females, can lead to cell lethality. Furthermore, methylation of certain repetitive sequences has been shown to be associated with the promoter CpG island hypomethylation (Kaneda et al., 2004) and may influence the expression of their neighbor genes (Schramke and Allshire, 2003 ). We propose that this level of change in global methylation may be crucial to cellular differentiation and may have distinct biological and clinical consequences.
In summary, we developed an improved quantitative COBRA LINE-1 method that is suitable for indirectly evaluating whole genome hypomethylation. This epigenetic change is relatively common and distinctive among different cellular differentiations. Global hypomethylation is one signature of most malignancies and may progressively evolve in multistage carcinogenesis. Additional investigations are warranted to further evaluate the potential use of COBRA LINE-1 as a tumor marker or in cancer molecular classification. 
